{"id":40191,"date":"2022-06-07T08:23:03","date_gmt":"2022-06-07T08:23:03","guid":{"rendered":"https:\/\/harchi90.com\/cannabis-related-products-demonstrate-short-term-reduction-in-chronic-pain\/"},"modified":"2022-06-07T08:23:03","modified_gmt":"2022-06-07T08:23:03","slug":"cannabis-related-products-demonstrate-short-term-reduction-in-chronic-pain","status":"publish","type":"post","link":"https:\/\/harchi90.com\/cannabis-related-products-demonstrate-short-term-reduction-in-chronic-pain\/","title":{"rendered":"Cannabis-Related Products Demonstrate Short-Term Reduction in Chronic Pain"},"content":{"rendered":"
\n
Summary: <\/em><\/strong>Cannabis products and synthetic, medical cannabis can help to relieve neuropathic pain, a new study reports.<\/em><\/p>\n
Source: <\/em><\/strong>Oregon Health and Science University<\/em><\/p>\n
Evidence behind the effectiveness of cannabis-related products to treat chronic pain is surprisingly thin, according to a new systematic evidence review by researchers at Oregon Health & Science University.<\/strong><\/p>\n
The federally funded review, which will be updated on an ongoing basis, was published today in the Annals of Internal Medicine<\/em>.<\/p>\n
Researchers did find evidence to support a short-term benefit in treating neuropathic pain \u2014 caused by damage to peripheral nerves, such as diabetic neuropathy resulting in pain described as burning and tingling, involving two FDA-approved synthetic products with 100% tetrahydrocannabinol, or THC : dronabinol (under the trade name Marinol) and nabilone (Cesamet). Both products also lead to notable side effects including sedation and dizziness, according to the review.<\/p>\n
Another product, a sublingual spray of equal parts THC and cannabidiol, or CBD, extracted from the cannabis plant, known as nabiximols, also showed evidence of some clinical benefit for neuropathic pain, although that product is not available in the US This product also led to side effects, such as nausea, sedation and dizziness.<\/p>\n
\u201cIn general, the limited amount of evidence surprised all of us,\u201d said lead author Marian S. McDonagh, Pharm.D., Emeritus professor of medical informatics and clinical epidemiology in the OHSU School of Medicine.<\/p>\n
“With so much buzz around cannabis-related products, and the easy availability of recreational and medical marijuana in many states, consumers and patients might assume there would be more evidence about the benefits and side effects.<\/p>\n
\u201cUnfortunately, there is very little scientifically valid research into most these products,\u201d she said. “We saw only a small group of observational cohort studies on cannabis products that would be easily available in states that allow it, and these were not designed to answer the important questions on treating chronic pain.”<\/p>\n
Voters in Oregon, Washington and 20 other states have legalized medical and recreational marijuana, however the researchers found many of the products now available at US dispensaries have not been well studied.<\/p>\n
“For some cannabis products, such as whole-plant products, the data are sparse with imprecise estimates of effect and studies had methodological limitations,” the authors write.<\/p>\n
This situation makes it difficult to guide patients.<\/p>\n
\u201cCannabis products vary quite a bit in terms of their chemical composition, and this could have important effects in terms of benefits and harm to patients,\u201d said co-author Roger Chou, MD, director of OHSU’s Pacific Northwest Evidence-based Practice Center. “That makes it tough for patients and clinicians since the evidence for one cannabis-based product may not be the same for another.”<\/p>\n